Jazz Pharmaceuticals Q2 Adj $4.51 Beats $4.43 Estimate, Sales $957.32M Beat $942.86M Estimate
Portfolio Pulse from Benzinga Newsdesk
Jazz Pharmaceuticals reported Q2 earnings of $4.51 per share, beating the analyst consensus estimate of $4.43 by 1.81%. This is a 4.88% increase from the same period last year. The company also reported quarterly sales of $957.32 million, beating the analyst consensus estimate of $942.86 million by 1.53%. This is a 2.62% increase from the same period last year.
August 09, 2023 | 8:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jazz Pharmaceuticals reported better than expected Q2 earnings and sales, which could positively impact its stock price.
Jazz Pharmaceuticals reported Q2 earnings and sales that beat analyst estimates. This positive financial performance could lead to an increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100